MAIA

MAIA Biotechnology Inc

1.13

Oct 22 • 1:57 PM ET -0.00 (-0.44%)

Healthcare Biotechnology USA Micro AMEX

Peers: BDTX CADL GERN ACRV NVCT CUE ONCY PDSB HURA KZIA

Index	-
Market Cap	70.08M
Enterprise Value	42.48M
Income	-26.85M
Sales	0.00M
Book/sh	0.34
Cash/sh	0.45
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Jul 28, 2022

P/E	-
Forward P/E	1.02
PEG	-
P/S	-
P/B	3.34
P/C	2.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.51
Current Ratio	4.51
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.63
EPS next Y	1.11
EPS next Q	-0.13
EPS this Y	22.86%
EPS next Y	305.56%
EPS next 5Y	-
EPS past 3/5Y	26.39% -2.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	-7.28%
Sales Y/Y TTM	-
EPS Q/Q	25.95%
Sales Q/Q	-
Earnings	Aug 11
EPS/Sales Surpr.	-18.18% -

Insider Own	16.98%
Insider Trans	4.05%
Inst Own	22.02%
Inst Trans	7.27%
ROA	-136.67%
ROE	-218.68%
ROIC	-129.84%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.88%
SMA50	-10.83%
SMA200	-22.98%
Trades

Shs Outstand	60.82M
Shs Float	51.26M
Short Float	5.25%
Short Ratio	5.62
Short Interest	2.69M
52W High	3.19 -64.42%
52W Low	0.87 30.46%
Volatility	5.78% 5.28%
ATR (14)	0.06
RSI (14)	42.45
Beta	0.28
Rel Volume	0.21
Avg Volume	478.55K
Volume	71,575

Perf Week	1.34%
Perf Month	-14.02%
Perf Quarter	-8.47%
Perf Half Y	-9.92%
Perf YTD	-25.82%
Perf Year	-16.54%
Perf 3Y	-52.31%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	14.00
Prev Close	1.14
Price	1.13
Change %	-0.44%

Oct-07-26 08:15AM	MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-23-26 09:17AM	MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal (GlobeNewswire)
Sep-22-26 08:47AM	MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-16-26 08:15AM	MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial (GlobeNewswire)
Sep-15-26 08:15AM	MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO (GlobeNewswire)
08:15AM	Loading…
Sep-10-26 08:15AM	MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 (GlobeNewswire)
Jul-08-26 09:45AM	MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial (GlobeNewswire)
Jun-25-26 08:08AM	MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer (GlobeNewswire)
Jun-18-26 08:30AM	MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University (GlobeNewswire) +6.06%
Jun-10-26 09:15AM	MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial (GlobeNewswire)
Jun-04-26 09:45AM	MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial (GlobeNewswire)
Jun-03-26 09:45AM	MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion (GlobeNewswire) +5.93%
Jun-02-26 09:45AM	MAIA Biotechnology Announces Open Market Purchases by CEO and Director (GlobeNewswire)
Jun-01-26 08:00AM	MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology (GlobeNewswire) -6.47%
Apr-16-26 09:20AM	MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer (GlobeNewswire) -6.34%
09:00AM	Loading…
Apr-08-26 09:00AM	MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy (GlobeNewswire)
Mar-31-26 09:15AM	MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +6.87%
Mar-04-26 04:00PM	MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Mar-02-26 10:45PM	MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.41% -27.05%
05:00PM	MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Feb-24-26 08:45AM	MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market (GlobeNewswire) +12.04%
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -10.75%
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire) -5.76%
Jan-20-26 10:15AM	MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum (GlobeNewswire) +26.44%
Dec-24-25 08:01AM	MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings (GlobeNewswire) +8.82%
Dec-16-25 04:15PM	MAIA Biotechnology Announces $1.51 Million Private Placement (GlobeNewswire) -8.89% -6.50%
Dec-11-25 01:00PM	MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates (GlobeNewswire) +18.84%
09:00AM	MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential (GlobeNewswire)
Dec-10-25 02:00PM	MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach (GlobeNewswire)
09:17AM	Loading…
Dec-01-25 09:17AM	MAIA Biotechnology Announces Open Market Purchases by CEO and Directors (GlobeNewswire)
Nov-21-25 09:01AM	MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 (GlobeNewswire)
Nov-20-25 08:47AM	MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation (GlobeNewswire) -5.33%
Oct-27-25 10:45AM	MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-23-25 08:36AM	MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +7.35%
Oct-13-25 04:20PM	MAIA Biotechnology Announces $736,600 Private Placement (GlobeNewswire) -6.37%
Oct-07-25 03:13PM	Cancer drug maker takes sudden pivot into crypto (TheStreet)
08:47AM	MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets (GlobeNewswire)
Sep-29-25 04:30PM	MAIA Biotechnology Announces $2.25 Million Private Placement (GlobeNewswire)
Sep-24-25 08:01AM	MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent (GlobeNewswire)
Sep-12-25 08:33AM	Maias NSCLC immunotherapy secures Phase II efficacy win (Clinical Trials Arena)
Sep-11-25 09:27AM	MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +8.97%
Sep-05-25 09:03AM	MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer (GlobeNewswire)
Aug-27-25 09:01AM	MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells (GlobeNewswire) +7.14%
Aug-18-25 08:00AM	Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) (GlobeNewswire)
Aug-13-25 09:01AM	MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy (GlobeNewswire)
Jul-28-25 08:01AM	MAIA Biotechnology Receives FDAs Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer (Business Wire)
Jul-17-25 09:17AM	MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy (Business Wire)
Jul-10-25 10:40AM	MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial (Clinical Trials Arena)
Jul-09-25 09:15AM	MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer (Business Wire) +9.24%
Jul-01-25 09:00AM	MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress (Business Wire) +6.67%
Jun-24-25 08:15AM	MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board (Business Wire)
Jun-19-25 09:25AM	MAIA Biotechnology, Roche sign supply agreement for cancer therapies (TipRanks)
Jun-18-25 09:15AM	MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies (Business Wire) +8.43%
Jun-10-25 08:46AM	MAIA Biotechnology to Present at BIO International Convention 2025 (Business Wire)
Jun-05-25 02:28PM	MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients (Benzinga) +10.80%
11:10AM	MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial (Business Wire)
08:04AM	MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer (Business Wire)
May-27-25 08:29PM	MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial (Insider Monkey)
05:35PM	CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 (Business Wire)
May-15-25 11:05AM	MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire)
May-14-25 10:15AM	MAIA Biotechnology Announces Director Participation in Recent Private Placement (Business Wire)
May-06-25 10:00AM	Best Momentum Stocks to Buy for May 6th (Zacks) +7.85%
07:41AM	New Strong Buy Stocks for May 6th (Zacks)
May-05-25 11:45PM	CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement (Business Wire) -6.83%
04:05PM	MAIA Biotechnology Announces $1.08 Million Private Placement (Business Wire)
Apr-01-25 08:30AM	MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders (Business Wire)
Mar-28-25 10:39AM	Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-27-25 12:00PM	MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-25-25 08:46AM	MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 (Business Wire) -5.99%
Mar-20-25 09:20AM	MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug (Business Wire)
Mar-19-25 11:00AM	MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO (Business Wire)
Feb-27-25 08:51AM	MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients (Business Wire) +7.07%
Feb-26-25 08:47AM	MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer (Business Wire) +5.75%
Feb-24-25 04:30PM	MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million (Business Wire)
Feb-18-25 03:44PM	MAIA Biotechnology Announces Private Placement of $2,715,000 (Business Wire)
Feb-04-25 08:51AM	MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer (Business Wire) +5.82%
Jan-10-25 09:45AM	MAIA Biotechnology to Present at Biotech Showcase 2025 (Business Wire)
Jan-07-25 09:12AM	MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications (Business Wire) +15.53%
Dec-19-24 08:47AM	MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings (Business Wire) +5.15%
Dec-16-24 08:37AM	MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas (Business Wire) +10.00%
Dec-09-24 06:00PM	MAIA Biotechnology Announces Private Placement of Approximately $950,000 (Business Wire)
Dec-03-24 08:17AM	MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer (Business Wire)
Nov-07-24 08:47AM	MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement (Business Wire)
Nov-05-24 09:45AM	MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Business Wire) +6.25%
Oct-28-24 07:00PM	MAIA Biotechnology Announces $2.44 Million Private Placement (Business Wire) +8.37%
Oct-15-24 08:15AM	MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-10-24 06:00AM	MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer (Business Wire) -5.75%
Sep-04-24 08:30AM	MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +15.75%
Jul-23-24 04:11AM	MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent (Business Wire)
Jun-07-24 12:31PM	MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDAs Approval of a Telomerase Inhibitor Agent Therapy (Business Wire) +16.27%
Jun-06-24 10:07AM	MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent (Business Wire)
Jun-04-24 08:41AM	MAIA Biotechnology Reveals New Clinical Data Showing THIOs Strong Efficacy in Non-Small Cell Lung Cancer (Business Wire) -26.27%
May-17-24 08:37AM	MAIA Biotechnology to Present at the BIO International Convention 2024 (Business Wire) +6.09%
May-16-24 08:37AM	MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (Business Wire) +8.71%
Apr-30-24 08:08AM	MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Business Wire) -8.72%
Apr-29-24 08:08AM	MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement (Business Wire) +9.18%
Apr-23-24 08:51AM	MAIA Biotechnology Announces $1.00 Million Private Placement (Business Wire) +8.85%
Apr-05-24 08:01AM	MAIA Biotechnology to Present at Two Investor Conferences in April 2024 (Business Wire) +6.82%
Mar-28-24 03:00PM	MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero (Business Wire) -11.29%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vitoc Vlad	Chief Executive Officer	Sep 14 '26	Buy	1.37	73,000	100,010	1,049,121	Sep 15 06:33 AM
Guerrero Ramiro	Director	Sep 10 '26	Buy	1.32	37,595	49,516	773,296	Sep 14 09:03 AM
Guerrero Ramiro	Director	Aug 27 '26	Buy	1.39	78,239	108,752	689,081	Sep 01 04:16 PM
Guerrero Ramiro	Director	Aug 28 '26	Buy	1.35	46,620	62,937	735,701	Sep 01 04:16 PM
Guerrero Ramiro	Director	Aug 26 '26	Buy	1.39	8,931	12,414	610,842	Sep 01 04:16 PM
Guerrero Ramiro	Director	Aug 24 '26	Buy	1.33	1,794	2,386	601,911	Aug 26 07:56 AM
Guerrero Ramiro	Director	Aug 20 '26	Buy	1.37	11,899	16,302	600,117	Aug 24 04:09 PM
Vitoc Vlad	Chief Executive Officer	Jun 01 '26	Buy	1.39	72,700	100,886	976,121	Jun 02 09:02 AM
Smith Stan	Director	Jun 01 '26	Buy	1.34	75,000	100,200	1,519,178	Jun 02 09:01 AM
Gryaznov Sergei	Chief Scientific Officer	Jun 01 '26	Buy	1.34	2,000	2,690	46,511	Jun 02 09:00 AM
Smith Stan	Director	Dec 22 '25	Buy	1.22	57,189	69,999	1,421,478	Dec 23 08:18 AM
CHAOUKI STEVEN M	Director	Dec 22 '25	Buy	1.22	40,849	49,999	151,873	Dec 23 08:16 AM
Louie Ngar Yee	Director	Dec 22 '25	Buy	1.22	81,699	100,000	1,248,888	Dec 23 08:14 AM
Smith Stan	Director	Dec 05 '25	Buy	1.20	13,740	16,441	4,580	Dec 09 04:51 PM
Vitoc Vlad	Chief Executive Officer	Nov 28 '25	Buy	1.14	50,000	56,830	881,421	Dec 01 06:20 AM
Vitoc Vlad	Chief Executive Officer	Nov 26 '25	Buy	1.05	22,000	23,019	853,421	Dec 01 06:20 AM
Luput Cristian	Director	Nov 26 '25	Buy	1.08	20,000	21,616	419,483	Dec 01 06:18 AM
Luput Cristian	Director	Nov 28 '25	Buy	1.11	18,145	20,230	437,628	Dec 01 06:18 AM
Smith Stan	Director	Nov 26 '25	Buy	1.04	15,000	15,582	1,364,289	Dec 01 06:14 AM
Luput Cristian	Director	Nov 25 '25	Buy	0.98	10,000	9,785	399,483	Nov 28 06:52 AM
Vitoc Vlad	Chief Executive Officer	Nov 25 '25	Buy	0.97	10,500	10,144	831,421	Nov 28 06:48 AM
Smith Stan	Director	Nov 25 '25	Buy	0.98	15,000	14,700	1,349,289	Nov 26 04:43 PM
Smith Stan	Director	Nov 24 '25	Buy	0.99	10,000	9,900	1,334,289	Nov 26 04:43 PM
Vitoc Vlad	Chief Executive Officer	Nov 24 '25	Buy	0.99	10,000	9,891	820,921	Nov 25 04:15 PM
Vitoc Vlad	Chief Executive Officer	Nov 21 '25	Buy	0.92	1,800	1,656	810,921	Nov 25 04:15 PM

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

M.D.Dr. Vlad Vitoc M.B.A.

Head of Finance and Principal Financial & Accounting OfficerMr. Jeffrey C. Himmelreich M.B.A.

Chief Scientific OfficerDr. Sergei M. Gryaznov Ph.D.

Company SecretaryLinda Moreira

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAIA

MAIA Biotechnology Inc

Upgrade your Finviz experience